Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences announces 1-for-30 stock consolidation

The consolidation will take effect from Monday and will bump up each share's value while reducing the number of shares in issue
Rising share price chart
After the reverse split, there will be around 1.06mln shares in issue

Pressure Biosciences Inc. ( OTCMKTS:PBIO ) has announced a one-for-thirty reverse split of its common stock to take effect next Monday.

The shares underlying the company's outstanding convertible securities will also be adjusted accordingly, the laboratory instruments designer told investors.

The reverse split will have the effect of reducing the number of shares each shareholder owns while at the same time increasing the value of each share, effectively leaving the value of each shareholder’s stake unchanged.

Once the reverse split - also known as a consolidation - has taken place, there will be around 1.06mln Pressure Bio shares in issue.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use